Skip to main content

Table 3 Clinical characteristics and outcomes of 5 patients with ILD (n = 5)

From: Interstitial lung disease associated with adjuvant and neoadjuvant chemotherapy in early breast cancer

Case

Diagnostic opportunity

SpO2a) (%)

KL-6a) (U/mL)

Gradeb)

CT findings

BAL and its diagnosis

Therapy for ILD

1

Continuous pyrexia

97

316

2

HR

Done, PCP

PSL + TMP/SMX

2

Continuous pyrexia

98

468

1

HR

Done, Negative

None

3

High KL-6, low SpO2

94

716

2

HR

None

PSL

4

E-CTc), low SpO2

94

338

2

OP

None

PSL

5

E-CT

98

346

2

HR

Done, PCP

TMP/SMX

  1. ILD interstitial lung disease, SpO2 percutaneous oxygen saturation, KL-6 serum Krebs von den Lungen-6, CT computed tomography, BAL bronchoalveolar lavage sampling, HR hypersensitivity reaction-like pattern, PCP Pneumocystis jiroveci pneumonia, PSL orally prednisolone (a day), TMP/SMX orally trimethoprim-sulfamethoxazole (a day), OP organizing pneumonia-like pattern
  2. aValues were at the onset of ILD. Standard value; SpO2 ≥ 95%, KL-6 < 500 U/mL
  3. bILD (pneumonitis) grade as in common terminology criteria for adverse events 5.0
  4. cCT to estimate the anti-cancer effect after epirubicin and cyclophosphamide